Key facts
- This page summarizes John Simard's Form 4 filing for XBiotech Inc. (XBIT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Feb 2022, 15:05.
John Simard - 15 Oct 2021 Form 4 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- XBIT
- Reported as of
- 15 Oct 2021
- Net transaction value
- -$657,724
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2022, 15:05:31 UTC
- Prior SEC filing
- 15 Oct 2021
- Next SEC filing
- 05 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Queena Han under Power of Attorney for John Simard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Simard filed Form 4 for XBiotech Inc. (XBIT) on 15 Feb 2022.
Change
- Previous filing in this sequence was filed on 15 Oct 2021.
- Current net transaction value: -$657,724.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XBIT
transaction
Common Stock
Sale
- Transaction value
- $226,471
- Shares
- -17,000
- Change %
- -0.44%
- Price
- $13.32
- Shares after
- 3,856,166
- Date
- 15 Oct 2021
- Ownership
- Direct
- Footnotes
- F1
XBIT
transaction
Common Stock
Sale
- Transaction value
- $431,254
- Shares
- -33,000
- Change %
- -0.86%
- Price
- $13.07
- Shares after
- 3,823,166
- Date
- 18 Oct 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
SEC remarks
John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 50,000 common stock on the open market as part of this 10B5-1 trading plan.